Distinguished in Colorectal Cancer

Dr. Jill Lacy

Oncology
Yale University
20 York St, 
New Haven, CT 
Offers Telehealth
Distinguished in Colorectal Cancer
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jill Lacy is an Oncologist in New Haven, Connecticut. Dr. Lacy is rated as a Distinguished provider by MediFind in the treatment of Colorectal Cancer. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, and Stomach Cancer.

Her clinical research consists of co-authoring 58 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 12 articles and participated in 2 clinical trials in the study of Colorectal Cancer.

Specialties
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Bridgeport Hospital
Greenwich Hospital Association -
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Nab-Paclitaxel, Gemcitabine, AB680 CD73 Inhibitor
Study Phase: Phase 1
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Enrollment Status: Completed
Publish Date: September 16, 2025
Intervention Type: Biological, Drug
Study Drugs: Olaparib, Ramucirumab
Study Phase: Phase 1/Phase 2
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Cobimetinib
Study Phase: Phase 2
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Procedure, Drug, Other
Study Drugs: Oxaliplatin, Leucovorin calcium, Irinotecan hydrochloride, Fluorouracil
Study Phase: Phase 2
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer
Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer
Enrollment Status: Completed
Publish Date: October 08, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Trial of Systemic Chemotherapy (Gemcitabine and Cisplatin) in Combination With Conventional Transarterial Chemoembolization (cTACE) in Patients With Advanced Intra-Hepatic Cholangiocarcinoma (ICC)
A Phase II Trial of Systemic Chemotherapy (Gemcitabine and Cisplatin) in Combination With Conventional Transarterial Chemoembolization (cTACE) in Patients With Advanced Intra-Hepatic Cholangiocarcinoma (ICC)
Enrollment Status: Terminated
Publish Date: December 30, 2019
Intervention Type: Drug
Study Phase: Phase 2
Randomized Phase II Trial of Chemoembolization and Sorafenib: Comparison Between Continuous and Sequential Treatment Regimens
Randomized Phase II Trial of Chemoembolization and Sorafenib: Comparison Between Continuous and Sequential Treatment Regimens
Enrollment Status: Withdrawn
Publish Date: January 10, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

58 Total Publications

Epigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC Profiling.
Epigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC Profiling.
Journal: bioRxiv : the preprint server for biology
Published: September 26, 2025
Similar Doctors
Elite in Colorectal Cancer
Dr. Charles S. Fuchs
Oncology | Hematology
Elite in Colorectal Cancer
Dr. Charles S. Fuchs
Oncology | Hematology
333 Cedar St, Yale Medical School, 
New Haven, CT 
 (0.1 miles away)
203-785-4672
Languages Spoken:
English
See accepted insurances

Charles Fuchs is an Oncologist and a Hematologist in New Haven, Connecticut. Dr. Fuchs is rated as a Distinguished provider by MediFind in the treatment of Colorectal Cancer. His top areas of expertise are Colorectal Cancer, Gastroesophageal Junction Cancer, Stomach Cancer, Pancreaticoduodenectomy, and Colonoscopy.

Elite in Colorectal Cancer
Dr. Alfred I. Neugut
Oncology | Hematology Oncology
Elite in Colorectal Cancer
Dr. Alfred I. Neugut
Oncology | Hematology Oncology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (61.4 miles away)
212-305-9876
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alfred Neugut is an Oncologist and a Hematologist Oncology provider in New York, New York. Dr. Neugut is rated as a Distinguished provider by MediFind in the treatment of Colorectal Cancer. His top areas of expertise are Colorectal Cancer, Breast Cancer, Familial Colorectal Cancer, Endoscopy, and Colonoscopy.

Distinguished in Colorectal Cancer
Dr. Jeremy S. Kortmansky
Hematology Oncology | Oncology
Distinguished in Colorectal Cancer
Dr. Jeremy S. Kortmansky
Hematology Oncology | Oncology

Yale University

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-688-4242
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Kortmansky is a Hematologist Oncology specialist and an Oncologist in New Haven, Connecticut. Dr. Kortmansky is rated as a Distinguished provider by MediFind in the treatment of Colorectal Cancer. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lacy's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 15 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile